Tag: antibody

Posted on

Moderna booster shot increases antibody levels against Omicron, company says

At this time, Moderna’s booster is administered as a 50-microgram dose. The business announcement noted that this dose elevated antibody concentrations 37-fold, as opposed with the amounts seen when a fully vaccinated particular person does not get a booster, and a 100-microgram dose greater antibody amounts 83-fold.

It remains unclear what these boosts imply as far as how well the booster doses clinically do the job towards Omicron.

“The remarkable raise in COVID-19 conditions from the Omicron variant is about to all. Nonetheless, these knowledge demonstrating that the currently licensed Moderna COVID-19 booster can strengthen neutralizing antibody ranges 37-fold higher than pre-boost amounts are reassuring,” Bancel mentioned.

'Boost everybody.' CEOs should mandate boosters before returning office workers, Andy Slavitt says

“To react to this remarkably transmissible variant, Moderna will keep on to rapidly progress an Omicron-specific booster applicant into medical tests in scenario it becomes necessary in the long run. We will also continue to produce and share data throughout our booster tactics with community health and fitness authorities to help them make evidence-based mostly conclusions on the very best vaccination procedures versus SARS-CoV-2.”

SARS-CoV-2 is the title of the coronavirus that triggers Covid-19.

It’s now up to US general public overall health authorities to contemplate no matter if Moderna’s coronavirus vaccine booster should really be specified at a larger dose, Dr. Stephen Hoge, president of the corporation, reported Monday.

“The selection of no matter if to deploy 100 micrograms or a better dose is seriously just one for public overall health organizations at this issue. We are just offering the information, and naturally we will share it with all people so that they can make that resolve,” Hoge stated through a enterprise meeting connect with.

Moderna spokesperson Colleen Hussey confirmed to CNN in an emailed assertion Monday that the firm is “sharing the data with regulators as they get started to evaluate if any adjustments to the authorized boosters will need to be created.”

Moderna’s present-day coronavirus vaccine booster is approved for emergency use for people today 18 and more mature in the United States and supplied as a fifty percent-dose at 50 micrograms, and it’s licensed at the 100-microgram dose for people today who are seriously immunocompromised, the assertion mentioned.

According to the US Facilities for Ailment Control and Prevention, about 32{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} of absolutely vaccinated adults — almost 60 million people today — have gotten a booster dose. Additional than 26.7 million of them have received a Moderna booster, in accordance to CDC details.

Separately, “we’re going to carry on to progress an Omicron-certain booster into medical trials in early 2022,” Hoge said Monday.

Covid-19 booster pictures can assist improve protection towards the Omicron coronavirus variant, and there is no will need for a variant-unique booster dose at this time, Dr. Anthony Fauci, director of the Nationwide Institute of Allergy and Infectious Ailments, said previous 7 days.

“A amount of experiments have been accomplished during the state and the world to take a glimpse at how we may get ready in the context of vaccinations,” Fauci claimed.

“The information remains crystal clear: If you are unvaccinated, get vaccinated,” included Fauci, the chief healthcare adviser to President Biden. “And especially in the arena of Omicron, if you are fully vaccinated, get your booster shot.”

Posted on

Antibody levels might help speed up approval

Share on Pinterest
New research suggests that antibody levels generated by vaccines could be an accurate way of measuring effectiveness. Image credit: Michaela Handrek-Rehle/Bloomberg via Getty Images.
  • Health authorities only approve the use of COVID-19 vaccines that have gone through rigorous clinical trials.
  • Scientists assess whether a vaccine is effective by checking whether participants in a trial develop the infection after having the vaccine.
  • In the present study, researchers find that a person’s antibody response could serve a correlate of effectiveness, instead of whether people develop the infection.
  • Using this proposed measure could speed up the regulatory approval of future vaccines.

In a new study, scientists have found that antibody levels can help indicate the effectiveness of the Moderna COVID-19 vaccine.

The research, published in the journal Science, may be the first step toward speeding up the regulatory approval process for future vaccines.

In theory, scientists could use antibody levels to identify vaccine effectiveness, rather than clinical trials to investigate how many vaccinated people develop severe COVID-19.

The speed with which scientists have developed vaccines for SARS-CoV-2, the virus that causes COVID-19, is unprecedented.

Previously, vaccine development typically took 10–15 years. By contrast, the Pfizer-BioNTech vaccine received emergency regulatory approval from the Food and Drug Administration (FDA) on December 11, 2020, less than a year after scientists first identified the virus.

However, researchers are still eager to reduce the time it takes to develop future vaccines.

Scientists may do this by identifying biomarkers that can stand in for the results of clinical trials. If these biomarkers can accurately predict how effective the vaccine is, it may obviate the need to see how many people develop the infection in a clinical trial.

Speaking to Medical News Today, Prof. Florian Kern, chair in immunology at the Brighton and Sussex Medical School, in the United Kingdom, said, “If it were possible to define a laboratory endpoint — in this case an immunological marker — that can tell us if someone is protected or not, it would be easier to measure the protective effect of a vaccine quickly and compare this effect to that of other vaccines.” Prof. Kern was not involved in the new study.

In the study, the researchers wanted to see whether antibodies produced in response to the Moderna COVID-19 vaccine could accurately predict whether the vaccine was effective.

They did this by analyzing data from the phase 3 trials of the vaccine. The researchers were looking at the level of binding and neutralizing antibodies produced and at certain properties of these antibodies.

The team focused on these biomarkers assessed at the point of the second vaccination and 4 weeks afterward.

The researchers found a clear link between higher levels of antibodies and greater protection against symptomatic COVID-19 .

Participants with antibody levels in the top 10{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} had a 10 times lower risk of symptomatic COVID-19 compared with participants who had undetectable or negative antibody values. This was the case no matter which antibody biomarker the researchers focused on.

MNT spoke with Dr. Peter Gilbert, a professor in the Vaccine and Infectious Disease Division of Fred Hutchinson Cancer Research Center, in Seattle, and the corresponding author of the study.

Summarizing the findings, Dr. Gilbert explained, “Four separate tests used to measure antibody levels in the blood showed that the higher a vaccine recipient’s antibody response, the less likely [they were] to experience symptomatic COVID-19.”

“The same measurements also indicated that higher antibody responses correlated with higher estimated vaccine efficacy against symptomatic COVID-19.”

“The findings are based on data from the phase 3 COVE trial, which enrolled more than 30,000 adult volunteers and established 94.1{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809} estimated vaccine efficacy against COVID-19 for the mRNA-1273 vaccine,” Dr. Gilbert added.

He also noted that the findings may help accelerate the approval process for future vaccines.

“Correlates of protection are surrogate markers of efficacy that can be used to reliably predict whether a vaccine will be protective, which can accelerate regulatory authorization and approval of vaccine candidates.”

“Rather than conducting large-scale clinical trials to establish vaccine efficacy, which can require tens of thousands of volunteers and can take months to years to complete, data collected from blood samples from smaller cohorts of vaccinated individuals can be evaluated using a particular test that would indicate whether a vaccine is likely to have clinical benefit in that population.”

– Dr. Peter Gilbert, corresponding author of the new study

The study authors caution that their investigation had a short follow-up period and included a relatively small number of COVID-19 cases. Also, the group did not consider the effects of booster vaccines or different variants of the virus, as these had not emerged when the trial was conducted. The trial had sampled a large and ethnically diverse number of participants for its immunogenicity measurements.

“While it may seem like an obvious finding that that more antibodies equates to higher levels of protection against COVID-19, this detailed analysis advances evidence toward establishing a correlate of protection that could be used to accelerate regulatory processes for variant-specific formulations of mRNA COVID-19 vaccines, as well as authorization of prototype mRNA COVID-19 vaccines in children,” said Dr. Gilbert.

For live updates on the latest developments regarding the novel coronavirus and COVID-19, click here.

Posted on

WHO update guideline on monoclonal antibody use

people in a hospital waiting room wearing masksShare on Pinterest
The new WHO guideline on using monoclonal antibodies for severe COVID-19 appears in the BMJ. Newsday LLC/Getty Images
  • The World Health Organization (WHO) recently updated a living guideline on COVID-19 drugs. In it, they conditionally recommend the use of monoclonal antibodies to treat patients with non-severe disease at highest risk for hospitalization and patients with severe or critical illness who have not mounted an antibody response.
  • The guideline is based on a meta-analysis of several studies and trials. In one of these trials, monoclonal antibody treatment with casirivimab and imdevimab reduced hospitalization risk by 71{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809}.
  • In another trial, treatment with monoclonal antibodies decreased the risk of death in patients with severe or critical COVID-19 who did not generate SARS-CoV-2 antibodies by 15{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809}.
  • Areas that need further research include accurate clinical guides to predict hospitalization risk in patients with non-severe COVID-19, determining optimal dosage and administration routes in non-severe and severe or critical COVID-19, and establishing safety and efficacy in children and during pregnancy.

The WHO recently updated a living guideline that provides recommendations for new COVID-19 drug treatments to include monoclonal antibodies (casirivimab and imdevimab).

Casirivimab and imdevimab are two laboratory-made proteins, similar to human antibodies, that target the spike protein of the SARS-CoV-2 virus, blocking its attachment and entry into the human cell.

The recommendations were published based on a systematic review of meta-analyses and large and international clinical trials. A meta-analysis in patients with non-severe disease showed monoclonal antibody treatment with casirivimab and imdevimab reduced hospitalization risk by 71{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809}.

Stay informed with live updates on the current COVID-19 outbreak and visit our coronavirus hub for more advice on prevention and treatment.

In the RECOVERY trial quoted by the WHO, treatment with monoclonal antibodies decreased the risk of death in seronegative patients with severe or critical COVID-19 by 15{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809}. Seronegative describes people whose blood serum tests revealed no antibodies for SARS-CoV-2.

In an interview with Medical News Today (MNT), Dr. William Schaffner, professor of infectious diseases at Vanderbilt University Medical Center, TN, explained: “Once people are infected, […] these antibodies can be given […] by intravenous infusion, and they will latch onto the virus, preventing it, thereby, from infecting more of our cells. If the virus cannot do that, it cannot evolve into creating more serious disease; in other words, the good guys cut the bad guys off at the pass.”

The WHO conditionally recommends treatment with casirivimab and imdevimab for those with non-severe COVID-19 at the highest risk for hospitalization. Their guideline appears in the BMJ.

In an MNT interview, according to the WHO, “This is the first drug that [the] WHO is recommending as a treatment for non-severe patients to reduce the risk of disease progression for those with the highest risks.”

People at increased risk for hospitalization include those who have not had the vaccination, people who are immunocompromised, older adults, people from racial and ethnic minority groups, people with disabilities, and people with other specific medical conditions.

A meta-analysis using data from 4,722 patients with non-severe COVID-19 in 4 randomized controlled trials showed that treatment with casirivimab and imdevimab reduced hospitalization risk by 71{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809}, resulting in 29 fewer hospitalizations per 1,000 patients. Monoclonal antibody treatment also reduced the duration of hospitalization by approximately 4 days.

The WHO also conditionally recommends using casirivimab and imdevimab to treat people with critical and severe COVID-19 who are seronegative.

The presence of acute respiratory distress syndrome, sepsis, or other conditions requiring mechanical ventilation or medications to increase extremely low blood pressure (vasopressors) meets the WHO definition for critical COVID-19 disease severity.

Additionally, the WHO defines severe COVID-19 as the presence of one of the following:

  • when the amount of oxygen in the blood, or oxygen saturation, is less than 90{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809}
  • symptoms of severe respiratory distress
    • inability to complete entire sentences
    • use of accessory muscle use
    • in children
      • grunting
      • chest wall indrawing, very extreme inward movement of lower chest on inspiration
      • central cyanosis, bluish discoloration of the skin, mucous membranes, lips, tongue, and nail beds

Results of a subgroup analysis of 2,823 patients in the RECOVERY trial demonstrated that treatment with casirivimab and imdevimab decreased the risk of death in seronegative patients with severe or critical COVID-19 by 15{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809}, resulting in 39 fewer deaths per 1000.

In this group, monoclonal antibody treatment reduced the need for mechanical ventilation by 13{cfdf3f5372635aeb15fd3e2aecc7cb5d7150695e02bd72e0a44f1581164ad809}.

Dr. Schaeffer explained that even though monoclonal antibody treatment is effective, there are many advantages to preemptive vaccination versus monoclonal antibody treatment.

“First of all, the vaccines are safe and effective, and they’re […] much cheaper. For example, vaccines cost U.S. taxpayers […] about $25, but monoclonal antibody treatment will cost over $2,000.”

He added, “Also, you don’t always get diagnosed early enough in order to take advantage of monoclonal therapy, and [it] is not given to everyone — you have to fit into a specific high-risk category in order to receive it. Lastly, […] monoclonal antibody is in relatively short supply — it’s now being rationed […] in the United States — and it may not even be available for everyone who needs it.”

The WHO Guideline Development Group panel acknowledges that obstacles to accessing the monoclonal antibody treatment may be particularly burdensome in some low-to-middle-income countries. The cost of the drug, special equipment needed for intravenous administration, rapid serological tests required for severely and critically ill patients, and special monitoring for allergic reactions, may pose challenges.

According to the WHO, “Some opportunities for further research into casirivimab and imdevimab include making sure there will be accurate clinical prediction guides to establish [the] individual patient risk of hospitalization in patients presenting with non-severe COVID-19 […] to best identify patients that would most benefit from this intervention, [determining best] dosage and administration routes in non-severe and severe/critical COVID-19 patients, and [establishing ]safety and efficacy in children and pregnant women.”

“Future research also includes the production of higher certainty and more relevant evidence to inform policy and practice, along with the emerging evidence in the rapidly changing landscape of trials for COVID-19.”

For live updates on the latest developments regarding the novel coronavirus and COVID-19, click here.